Edge Medical listed on the Hong Kong Stock Exchange in late December 2025, with trading scheduled to begin in early January 2026 under the stock code 2675.HK. The listing followed a confidential filing process that Bloomberg reported in August 2025, and draws on a Chapter 18A pathway designed for pre-profit biomedical technology companies — a route that has become the preferred IPO structure for Chinese medical device makers with international ambitions.
The Path to Listing
Shenzhen Edge Medical Co., Ltd. was founded in May 2017 by Wang Jianchen and Gao Yuanqing, engineers from Tianjin University. The company entered a crowded development period for Chinese laparoscopic surgical robots but distinguished itself by reaching NMPA approval for two separate platforms — the MP1000 multi-port system in December 2022 and the SP1000 single-port system in November 2023 — ahead of most domestic peers.
Pre-IPO capital formation was substantial. Edge Medical completed multiple funding rounds totaling over RMB 2.19 billion, according to the company’s IPO prospectus. Investors included Sequoia China, Temasek, Boyu Capital, Legend Star, and Tencent. Temasek’s presence in the cap table was a signal to international institutional investors: the Singapore sovereign investment firm has a healthcare technology mandate and the credibility to validate clinical-stage medical device companies for international markets.
Bloomberg reported in August 2025 that Edge Medical had confidentially filed for the Hong Kong listing. The confidential filing mechanism — available to qualifying companies on the HKEX main board — allows issuers to test regulatory and investor feedback without immediate public disclosure. The company proceeded to a public filing and listing approval, with the December 2025 listing date announced through HKEX formal channels.
The IPO raised approximately HK$1.2 billion, according to Edge Medical. Cornerstone investors included Abu Dhabi Investment Authority (ADIA), Tencent, OrbiMed, and UBS Asset Management. Shares opened on the first trading day at HK$59, representing a 36.45% premium to the IPO price of HK$43.24, according to the company’s disclosure.
Product Portfolio Across Three Platforms
Edge Medical’s commercial case rests on three distinct robotic surgery platforms, each targeting a different access pathway for minimally invasive procedures.
MP1000 multi-port system. The MP1000 is a four-arm laparoscopic robot with seven degrees of freedom per arm. It received NMPA approval in December 2022 and CE Mark certification in March 2025. A distinctive feature is the system’s fluorescence imaging capability — the only such approved functionality among Chinese-brand surgical robots at the time of CE certification, according to Edge Medical. By June 2025, the company had signed cumulative global sales agreements for 61 MP1000 systems across more than 20 countries, according to the prospectus.
SP1000 single-port system. The SP1000 performs minimally invasive procedures through a single small incision. It received NMPA approval in November 2023 and CE Mark certification in October 2025. According to Frost & Sullivan, cited in the prospectus, it was the first domestically approved single-port laparoscopic robot to cover three or more major surgical specialties. Over 2,000 robot-assisted clinical procedures had been completed using the SP1000 by the last practicable date before the IPO.
Bronchoscope robot. Edge Medical received NMPA approval for its bronchoscope robot in January 2025, entering a flexible robotic bronchoscopy segment that also saw MicroPort MedBot’s UniPath receive NMPA clearance in December 2025. Edge Medical began commercializing the bronchoscope system in September 2025.
The MSP2000 — an integrated platform combining multi-port and single-port capability in a single system — received CE Mark certification in October 2025 alongside the SP1000. Edge Medical described it as the first integrated single- and multi-port robotic surgical platform to receive CE certification, according to the company.
Commercial Momentum in H1 2025
The operating data disclosed in Edge Medical’s prospectus was the most closely watched figure in the filing. The company reported 25 commercial orders across nearly 20 countries in H1 2025, according to the company — a pace that placed it among the most commercially active Chinese surgical robot makers at the time of filing.
Revenue grew from RMB 48.0 million in 2023 to RMB 160 million in 2024, with H1 2025 revenue reaching RMB 149 million — roughly matching full-year 2024 in six months, according to the prospectus. Gross margins held at approximately 61–63%. The company reported net losses of RMB 213 million in 2023, RMB 219 million in 2024, and RMB 89 million in H1 2025, consistent with the capital investment profile of a pre-profitability commercial stage company.
Domestically in 2024, Edge Medical sold 20 MP1000 units, ranking first among Chinese manufacturers in tender wins that year, according to the company. Over 12,000 robot-assisted clinical surgeries had been performed using the MP1000 in China.
Chapter 18A and the Hong Kong Pathway
Edge Medical’s listing under Chapter 18A of the HKEX Listing Rules is part of a broader trend in Chinese medical device finance. Chapter 18A, introduced by HKEX in 2018, permits pre-revenue or pre-profit biomedical technology companies to list on the main board provided they meet market capitalization and other criteria. It was designed to attract healthcare innovation companies that would otherwise pursue a Nasdaq or A-share listing, and has drawn a significant cohort of Chinese medical technology companies since its introduction.
For surgical robot makers specifically, Hong Kong offers advantages over alternative venues. The dual-currency (HKD/RMB) infrastructure facilitates international institutional participation. The HKEX research analyst community has deep familiarity with Chinese healthcare issuers. And the exchange’s time zone and legal framework are more accessible to Southeast Asian, European, and Middle Eastern institutional investors than US exchanges — markets that Edge Medical and its peers are actively entering commercially.
The pattern established by Edge Medical follows one set by Cornerstone Robotics, which also operates out of Hong Kong and closed approximately $270 million in funding across two 2025 rounds. Whether other Chinese surgical robot companies follow with their own Hong Kong listings will be one of the funding structure questions to watch in 2026.
Outlook
Edge Medical’s public listing shifts its operating context in several ways. Quarterly disclosure requirements create transparency obligations that private companies avoid. The capital raised provides runway for international commercialization, with the company planning approximately 20 additional regional training centers globally over two to three years, according to the prospectus.
The competitive environment it enters as a public company is more crowded than when the MP1000 first shipped. MicroPort MedBot, Surgerii Robotics, and others are simultaneously pursuing CE-certified international commercial programs. The differentiation Edge Medical emphasizes — a three-platform portfolio with NMPA and CE approval on all commercial systems, the fluorescence imaging capability on MP1000, and its Edge Cloud remote surgery platform, which the company reported has completed over 500 procedures globally — will need to hold up in competitive hospital procurement contexts where multiple Chinese robot options now exist alongside established international platforms.
In the flexible bronchoscopy segment, both Edge Medical and MicroPort MedBot now have NMPA-cleared systems entering commercialization simultaneously. This overlap creates direct competitive pressure in what the year-in-review analysis identified as one of the key category races for 2026, given early-stage lung cancer detection volumes in China.